2016
Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer
Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. Journal Of Clinical Investigation 2016, 126: 4157-4173. PMID: 27721235, PMCID: PMC5096908, DOI: 10.1172/jci87252.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsErbB ReceptorsFemaleHeterograftsHumansIntercellular Adhesion Molecule-1Macrophage-1 AntigenMacrophagesMiceMice, NudeNeoplasm MetastasisNeoplasm ProteinsNeoplasm TransplantationOvarian NeoplasmsSpheroids, CellularVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1ConceptsTumor-associated macrophagesOvarian cancerTranscoelomic metastasisTumor cellsICAM-1Mouse modelEpithelial ovarian cancerOvarian cancer growthOvarian cancer metastasisSpheroid formationOvarian cancer progressionVEGF/VEGFRTumor cell proliferationPharmacological blockadeMetastatic cancerColon cancerCancer growthMetastasisAntibody neutralizationTumor growthCancerClinical pathologyCancer metastasisCancer progressionΑMβ2 integrinImproved i.p. drug delivery with bioadhesive nanoparticles
Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM. Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 11453-11458. PMID: 27663731, PMCID: PMC5068292, DOI: 10.1073/pnas.1523141113.Peer-Reviewed Original ResearchConceptsChemotherapeutic agentsUterine serous carcinoma patientsBioadhesive nanoparticlesAdministration of chemotherapySerous carcinoma patientsPotent chemotherapeutic agentPeritoneal carcinomatosisCarcinoma patientsPeritoneal spaceAbdominal cavityLow systemic toxicityLymphatic drainageTherapeutic efficacyMesothelial cellsHigh therapeutic efficacySystemic toxicityFast clearanceEfficacy of nanoparticlesEfficacyFree EBBiodegradable nanoparticlesNanoparticlesDrug deliveryCarcinomatosisChemotherapy
1996
Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat
Government. T, Rose, Tocco, Granger, DiSaia, Hamilton, Santin, Hiserodt. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. American Journal Of Obstetrics And Gynecology 1996, 175: 593-599. PMID: 8828419, DOI: 10.1053/ob.1996.v175.a73595.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsDisease Models, AnimalEpitheliumFemaleFlow CytometryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInjections, IntraperitonealIntercellular Adhesion Molecule-1MiceMice, NudeNeoplasm TransplantationOvarian NeoplasmsRatsRats, Inbred F344Tumor Cells, CulturedConceptsNuTu-19 cellsMajor histocompatibility complex class IEpithelial ovarian cancerHistocompatibility complex class IFischer 344 ratsComplex class IOvarian cancerCell surface antigensAnimal modelsAnimal survivalSurface antigenMajor histocompatibility complex class II antigensOvarian cancer animal modelKaplan-Meier survival analysisHuman ovarian epithelial carcinomaTumor cellsCell linesClass IClass II antigensExperimental animal modelsViable tumor cellsFemale athymic miceOvarian epithelial carcinomaParental tumor cellsUseful animal modelDevelopment and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules
Santin A, Ioli G, Hiserodt J, Manetta A, Pecorelli S, DiSaia P, Granger G. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. American Journal Of Obstetrics And Gynecology 1996, 174: 633-640. PMID: 8623798, DOI: 10.1016/s0002-9378(96)70441-6.Peer-Reviewed Original ResearchConceptsIL-2Interleukin-2Ovarian carcinoma cellsOvarian cancerAllogeneic peripheral blood lymphocytesAdvanced epithelial ovarian cancerBALB/c nude miceChromium-51 release assaysMajor histocompatibility complex class IAdvance ovarian cancerCarcinoma cellsHistocompatibility complex class IEpithelial ovarian cancerMajor histocompatibility complex moleculesPeripheral blood lymphocytesHuman ovarian carcinoma cell linesHuman ovarian carcinoma cellsOvarian carcinoma cell linesComplex class ICytokine interleukin-2Long-term cytotoxicHistocompatibility complex moleculesMonths of studyUCI-107Tumor vaccines